Janux Therapeutics (JANX) Share-based Compensation (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Share-based Compensation data on file, last reported at $28.5 million in Q1 2026.

• On a quarterly basis, Share-based Compensation rose 166.31% year-over-year to $28.5 million in Q1 2026; TTM through Mar 2026 was $28.5 million, a 25.19% decrease from a year earlier, with the FY2025 full-year figure at $57.6 million, up 74.44% from the prior year.
• Share-based Compensation for Q1 2026 stood at $28.5 million, up from $9.5 million in the prior quarter.
• Over the last five years, Share-based Compensation for JANX reached as high as $75.9 million in Q2 2025 and fell as low as $4.0 million in Q1 2022.
• Historically, Share-based Compensation has averaged $15.1 million across 5 years, with a median of $5.6 million in 2024.
• Across the five-year window, Share-based Compensation jumped 1323.74% in 2022 and dropped 1.04% in 2023, its largest moves.
• Year by year, Share-based Compensation stood at $4.2 million in 2022, then advanced by 6.61% to $4.5 million in 2023, then soared by 39.44% to $6.3 million in 2024, then surged by 52.22% to $9.5 million in 2025, then surged by 199.53% to $28.5 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $28.5 million in Q1 2026, $9.5 million in Q4 2025, and $61.2 million in Q3 2025.